Proceedings of the 2017 ISEV symposium on “HIV, NeuroHIV, drug abuse, & EVs”

Guoku Hu, Sowmya V Yelamanchili, Fatah Kashanchi, Norman Haughey, Vincent C. Bond, Kenneth W. Witwer, Lynn Pulliam, Shilpa J Buch

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Despite the success of combination antiretroviral therapy (cART), there is increased prevalence of HIV-associated neurocognitive disorders (HAND) in HIV-1-infected individuals on cART, which poses a major health care challenge. Adding further complexity to this long-term antiretroviral use is the comorbidity with drugs of abuse such as morphine, cocaine, and methamphetamine, which can in turn, exacerbate neurologic and cognitive deficits associated with HAND. Furthermore, HIV proteins, such as the transactivator of transcription (Tat) and the envelope protein (gp120), as well as antiretrovirals themselves can also contribute to the progression of neurodegeneration underlying HAND. In the field of NeuroHIV and drug addiction, EVs hold the potential to serve as biomarkers of cognitive dysfunction, targets of therapy, and as vehicles for therapeutic delivery of agents that can ameliorate disease pathogenesis. Based on the success of a previous Satellite Symposium in 2015 at the ISEV meeting in Washington, experts again expanded on their latest research findings in the field, shedding light on the emerging trends in the field of Extracellular Vesicle (EV) biology in NeuroHIV and drug abuse. The satellite symposium sought to align experts in the fields of NeuroHIV and drug abuse to share their latest insights on the role of EVs in regulating neuroinflammation, neurodegeneration, peripheral immune response, and HIV latency in HIV-infected individuals with or without the comorbidity of drug abuse.

Original languageEnglish (US)
Pages (from-to)935-940
Number of pages6
JournalJournal of neurovirology
Volume23
Issue number6
DOIs
StatePublished - Dec 1 2017

Fingerprint

Substance-Related Disorders
HIV
Comorbidity
Human Immunodeficiency Virus Proteins
Trans-Activators
Methamphetamine
Street Drugs
Therapeutics
Neurologic Manifestations
Cocaine
Morphine
Reaction Time
HIV-1
Biomarkers
Delivery of Health Care
Research
Neurocognitive Disorders
Proteins

Keywords

  • Drug abuse
  • Extracellular vesicles (EVs)
  • HIV-associated neurocognitive disorders (HAND)
  • Human immunodeficiency virus (HIV)
  • NeuroHIV

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Virology

Cite this

Proceedings of the 2017 ISEV symposium on “HIV, NeuroHIV, drug abuse, & EVs”. / Hu, Guoku; Yelamanchili, Sowmya V; Kashanchi, Fatah; Haughey, Norman; Bond, Vincent C.; Witwer, Kenneth W.; Pulliam, Lynn; Buch, Shilpa J.

In: Journal of neurovirology, Vol. 23, No. 6, 01.12.2017, p. 935-940.

Research output: Contribution to journalArticle

Hu, Guoku ; Yelamanchili, Sowmya V ; Kashanchi, Fatah ; Haughey, Norman ; Bond, Vincent C. ; Witwer, Kenneth W. ; Pulliam, Lynn ; Buch, Shilpa J. / Proceedings of the 2017 ISEV symposium on “HIV, NeuroHIV, drug abuse, & EVs”. In: Journal of neurovirology. 2017 ; Vol. 23, No. 6. pp. 935-940.
@article{5dfab59d5f88467fb5d50506b5fdde49,
title = "Proceedings of the 2017 ISEV symposium on “HIV, NeuroHIV, drug abuse, & EVs”",
abstract = "Despite the success of combination antiretroviral therapy (cART), there is increased prevalence of HIV-associated neurocognitive disorders (HAND) in HIV-1-infected individuals on cART, which poses a major health care challenge. Adding further complexity to this long-term antiretroviral use is the comorbidity with drugs of abuse such as morphine, cocaine, and methamphetamine, which can in turn, exacerbate neurologic and cognitive deficits associated with HAND. Furthermore, HIV proteins, such as the transactivator of transcription (Tat) and the envelope protein (gp120), as well as antiretrovirals themselves can also contribute to the progression of neurodegeneration underlying HAND. In the field of NeuroHIV and drug addiction, EVs hold the potential to serve as biomarkers of cognitive dysfunction, targets of therapy, and as vehicles for therapeutic delivery of agents that can ameliorate disease pathogenesis. Based on the success of a previous Satellite Symposium in 2015 at the ISEV meeting in Washington, experts again expanded on their latest research findings in the field, shedding light on the emerging trends in the field of Extracellular Vesicle (EV) biology in NeuroHIV and drug abuse. The satellite symposium sought to align experts in the fields of NeuroHIV and drug abuse to share their latest insights on the role of EVs in regulating neuroinflammation, neurodegeneration, peripheral immune response, and HIV latency in HIV-infected individuals with or without the comorbidity of drug abuse.",
keywords = "Drug abuse, Extracellular vesicles (EVs), HIV-associated neurocognitive disorders (HAND), Human immunodeficiency virus (HIV), NeuroHIV",
author = "Guoku Hu and Yelamanchili, {Sowmya V} and Fatah Kashanchi and Norman Haughey and Bond, {Vincent C.} and Witwer, {Kenneth W.} and Lynn Pulliam and Buch, {Shilpa J}",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s13365-017-0599-8",
language = "English (US)",
volume = "23",
pages = "935--940",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Proceedings of the 2017 ISEV symposium on “HIV, NeuroHIV, drug abuse, & EVs”

AU - Hu, Guoku

AU - Yelamanchili, Sowmya V

AU - Kashanchi, Fatah

AU - Haughey, Norman

AU - Bond, Vincent C.

AU - Witwer, Kenneth W.

AU - Pulliam, Lynn

AU - Buch, Shilpa J

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Despite the success of combination antiretroviral therapy (cART), there is increased prevalence of HIV-associated neurocognitive disorders (HAND) in HIV-1-infected individuals on cART, which poses a major health care challenge. Adding further complexity to this long-term antiretroviral use is the comorbidity with drugs of abuse such as morphine, cocaine, and methamphetamine, which can in turn, exacerbate neurologic and cognitive deficits associated with HAND. Furthermore, HIV proteins, such as the transactivator of transcription (Tat) and the envelope protein (gp120), as well as antiretrovirals themselves can also contribute to the progression of neurodegeneration underlying HAND. In the field of NeuroHIV and drug addiction, EVs hold the potential to serve as biomarkers of cognitive dysfunction, targets of therapy, and as vehicles for therapeutic delivery of agents that can ameliorate disease pathogenesis. Based on the success of a previous Satellite Symposium in 2015 at the ISEV meeting in Washington, experts again expanded on their latest research findings in the field, shedding light on the emerging trends in the field of Extracellular Vesicle (EV) biology in NeuroHIV and drug abuse. The satellite symposium sought to align experts in the fields of NeuroHIV and drug abuse to share their latest insights on the role of EVs in regulating neuroinflammation, neurodegeneration, peripheral immune response, and HIV latency in HIV-infected individuals with or without the comorbidity of drug abuse.

AB - Despite the success of combination antiretroviral therapy (cART), there is increased prevalence of HIV-associated neurocognitive disorders (HAND) in HIV-1-infected individuals on cART, which poses a major health care challenge. Adding further complexity to this long-term antiretroviral use is the comorbidity with drugs of abuse such as morphine, cocaine, and methamphetamine, which can in turn, exacerbate neurologic and cognitive deficits associated with HAND. Furthermore, HIV proteins, such as the transactivator of transcription (Tat) and the envelope protein (gp120), as well as antiretrovirals themselves can also contribute to the progression of neurodegeneration underlying HAND. In the field of NeuroHIV and drug addiction, EVs hold the potential to serve as biomarkers of cognitive dysfunction, targets of therapy, and as vehicles for therapeutic delivery of agents that can ameliorate disease pathogenesis. Based on the success of a previous Satellite Symposium in 2015 at the ISEV meeting in Washington, experts again expanded on their latest research findings in the field, shedding light on the emerging trends in the field of Extracellular Vesicle (EV) biology in NeuroHIV and drug abuse. The satellite symposium sought to align experts in the fields of NeuroHIV and drug abuse to share their latest insights on the role of EVs in regulating neuroinflammation, neurodegeneration, peripheral immune response, and HIV latency in HIV-infected individuals with or without the comorbidity of drug abuse.

KW - Drug abuse

KW - Extracellular vesicles (EVs)

KW - HIV-associated neurocognitive disorders (HAND)

KW - Human immunodeficiency virus (HIV)

KW - NeuroHIV

UR - http://www.scopus.com/inward/record.url?scp=85034227478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034227478&partnerID=8YFLogxK

U2 - 10.1007/s13365-017-0599-8

DO - 10.1007/s13365-017-0599-8

M3 - Article

C2 - 29147885

AN - SCOPUS:85034227478

VL - 23

SP - 935

EP - 940

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 6

ER -